Table 1.
Prevention of EAMG by intranasal treatment with AChoR fragments
| Treatment | Clinical score, no./total*
|
Healthy rats, % | Δ weight 3–7 weeks, g | AChoR content†
|
|||||
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | fmol/mg protein | % | |||
| Control vehicle, GST | 0/10 | 2/10 | 2/10 | 4/10 | 2/10 | 0 | −12.8 ± 9.2 | 17.5 ± 4.1 | 44 |
| Hα122-210 | 3/9 | 3/9 | 1/9 | 1/9 | 1/9 | 33 | +9.2 ± 8.6 | 14.9 ± 1.7 | 38 |
| Hα1-121 | 5/9 | 1/9 | 2/9 | 0/9 | 1/9 | 56 | +13.6 ± 2.5 | 29.6 ± 4.5 | 75 |
| Hα1-210 | 6/9 | 1/9 | 1/9 | 0/9 | 1/9 | 67 | +15.0 ± 6.3 | 35.0 ± 3.4 | 89 |
*
Evaluated 8 weeks after the induction of EAMG.
†
Muscle AChoR content in normal age matched rats was 39.5 ± 2.5 fmol/mg protein and was referred to as the 100% value for this experiment.